vs

Side-by-side financial comparison of BRIGHT HORIZONS FAMILY SOLUTIONS INC. (BFAM) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

BRIGHT HORIZONS FAMILY SOLUTIONS INC. is the larger business by last-quarter revenue ($733.7M vs $622.0M, roughly 1.2× Royalty Pharma plc). On growth, BRIGHT HORIZONS FAMILY SOLUTIONS INC. posted the faster year-over-year revenue change (8.8% vs 4.8%). Over the past eight quarters, BRIGHT HORIZONS FAMILY SOLUTIONS INC.'s revenue compounded faster (8.5% CAGR vs 4.6%).

Bright Horizons Family Solutions Inc. is a United States–based child-care provider and is the largest provider of employer-sponsored child care. It also provides back-up child care and elder care, tuition program management, education advising, and student loan repayment programs. It is headquartered in Newton, Massachusetts.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BFAM vs RPRX — Head-to-Head

Bigger by revenue
BFAM
BFAM
1.2× larger
BFAM
$733.7M
$622.0M
RPRX
Growing faster (revenue YoY)
BFAM
BFAM
+4.1% gap
BFAM
8.8%
4.8%
RPRX
Faster 2-yr revenue CAGR
BFAM
BFAM
Annualised
BFAM
8.5%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BFAM
BFAM
RPRX
RPRX
Revenue
$733.7M
$622.0M
Net Profit
$214.2M
Gross Margin
19.3%
Operating Margin
6.2%
62.4%
Net Margin
34.4%
Revenue YoY
8.8%
4.8%
Net Profit YoY
2.9%
EPS (diluted)
$0.38
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BFAM
BFAM
RPRX
RPRX
Q4 25
$733.7M
$622.0M
Q3 25
$802.8M
$609.3M
Q2 25
$731.6M
$578.7M
Q1 25
$665.5M
$568.2M
Q4 24
$674.1M
$593.6M
Q3 24
$719.1M
$564.7M
Q2 24
$670.1M
$537.3M
Q1 24
$622.7M
$568.0M
Net Profit
BFAM
BFAM
RPRX
RPRX
Q4 25
$214.2M
Q3 25
$78.6M
$288.2M
Q2 25
$54.8M
$30.2M
Q1 25
$38.0M
$238.3M
Q4 24
$208.2M
Q3 24
$54.9M
$544.0M
Q2 24
$39.2M
$102.0M
Q1 24
$17.0M
$4.8M
Gross Margin
BFAM
BFAM
RPRX
RPRX
Q4 25
19.3%
Q3 25
27.0%
Q2 25
25.0%
Q1 25
23.4%
Q4 24
20.8%
Q3 24
25.2%
Q2 24
24.2%
Q1 24
21.7%
Operating Margin
BFAM
BFAM
RPRX
RPRX
Q4 25
6.2%
62.4%
Q3 25
15.1%
70.1%
Q2 25
11.8%
36.3%
Q1 25
9.4%
94.0%
Q4 24
7.2%
60.9%
Q3 24
12.4%
Q2 24
10.3%
50.2%
Q1 24
6.4%
-13.0%
Net Margin
BFAM
BFAM
RPRX
RPRX
Q4 25
34.4%
Q3 25
9.8%
47.3%
Q2 25
7.5%
5.2%
Q1 25
5.7%
41.9%
Q4 24
35.1%
Q3 24
7.6%
96.3%
Q2 24
5.8%
19.0%
Q1 24
2.7%
0.8%
EPS (diluted)
BFAM
BFAM
RPRX
RPRX
Q4 25
$0.38
$0.49
Q3 25
$1.37
$0.67
Q2 25
$0.95
$0.07
Q1 25
$0.66
$0.55
Q4 24
$0.50
$0.46
Q3 24
$0.94
$1.21
Q2 24
$0.67
$0.23
Q1 24
$0.29
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BFAM
BFAM
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$140.1M
$618.7M
Total DebtLower is stronger
$747.6M
$9.0B
Stockholders' EquityBook value
$1.3B
$9.7B
Total Assets
$3.9B
$19.6B
Debt / EquityLower = less leverage
0.56×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BFAM
BFAM
RPRX
RPRX
Q4 25
$140.1M
$618.7M
Q3 25
$116.6M
$938.9M
Q2 25
$179.2M
$631.9M
Q1 25
$112.0M
$1.1B
Q4 24
$110.3M
$929.0M
Q3 24
$109.9M
$950.1M
Q2 24
$140.2M
$1.8B
Q1 24
$63.7M
$843.0M
Total Debt
BFAM
BFAM
RPRX
RPRX
Q4 25
$747.6M
$9.0B
Q3 25
$747.5M
$8.9B
Q2 25
$797.0M
$8.0B
Q1 25
$872.7M
$7.6B
Q4 24
$918.4M
$7.6B
Q3 24
$925.7M
$7.6B
Q2 24
$931.9M
$7.6B
Q1 24
$938.1M
$6.1B
Stockholders' Equity
BFAM
BFAM
RPRX
RPRX
Q4 25
$1.3B
$9.7B
Q3 25
$1.4B
$9.6B
Q2 25
$1.4B
$9.5B
Q1 25
$1.3B
$9.8B
Q4 24
$1.3B
$10.3B
Q3 24
$1.4B
$10.3B
Q2 24
$1.3B
$9.8B
Q1 24
$1.2B
$9.9B
Total Assets
BFAM
BFAM
RPRX
RPRX
Q4 25
$3.9B
$19.6B
Q3 25
$3.9B
$19.3B
Q2 25
$3.9B
$18.3B
Q1 25
$3.8B
$17.6B
Q4 24
$3.9B
$18.2B
Q3 24
$3.9B
$18.0B
Q2 24
$3.8B
$17.7B
Q1 24
$3.8B
$16.1B
Debt / Equity
BFAM
BFAM
RPRX
RPRX
Q4 25
0.56×
0.92×
Q3 25
0.52×
0.93×
Q2 25
0.57×
0.84×
Q1 25
0.66×
0.78×
Q4 24
0.72×
0.74×
Q3 24
0.66×
0.74×
Q2 24
0.73×
0.78×
Q1 24
0.76×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BFAM
BFAM
RPRX
RPRX
Operating Cash FlowLast quarter
$350.7M
$827.1M
Free Cash FlowOCF − Capex
$258.5M
FCF MarginFCF / Revenue
35.2%
Capex IntensityCapex / Revenue
12.6%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$402.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BFAM
BFAM
RPRX
RPRX
Q4 25
$350.7M
$827.1M
Q3 25
$-17.6M
$702.6M
Q2 25
$134.2M
$364.0M
Q1 25
$86.2M
$596.1M
Q4 24
$337.5M
$742.5M
Q3 24
$-8.9M
$703.6M
Q2 24
$109.4M
$658.2M
Q1 24
$116.3M
$664.6M
Free Cash Flow
BFAM
BFAM
RPRX
RPRX
Q4 25
$258.5M
Q3 25
$-42.4M
Q2 25
$115.4M
Q1 25
$70.9M
Q4 24
$240.2M
Q3 24
$-32.2M
Q2 24
$86.8M
Q1 24
$96.9M
FCF Margin
BFAM
BFAM
RPRX
RPRX
Q4 25
35.2%
Q3 25
-5.3%
Q2 25
15.8%
Q1 25
10.7%
Q4 24
35.6%
Q3 24
-4.5%
Q2 24
13.0%
Q1 24
15.6%
Capex Intensity
BFAM
BFAM
RPRX
RPRX
Q4 25
12.6%
Q3 25
3.1%
Q2 25
2.6%
Q1 25
2.3%
Q4 24
14.4%
Q3 24
3.2%
Q2 24
3.4%
Q1 24
3.1%
Cash Conversion
BFAM
BFAM
RPRX
RPRX
Q4 25
3.86×
Q3 25
-0.22×
2.44×
Q2 25
2.45×
12.06×
Q1 25
2.26×
2.50×
Q4 24
3.57×
Q3 24
-0.16×
1.29×
Q2 24
2.79×
6.45×
Q1 24
6.85×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BFAM
BFAM

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons